Every partnership ICON has entered into is still ongoing and evolving with our clients’ needs

Since our inception in 1990 we’ve strived to work as a ‘trusted partner’ to our clients, collaborating, innovating and finding new ways together to improve outcomes.

ICON has worked with many of the world’s pharmaceutical firms, developing strategic partnerships with some of the world’s largest. Our award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

Our partnership models seek to integrate our own multidisciplinary expertise and that of our clients, resulting in more efficient trial design, effective utilisation of digital technologies and real world data, and optimal patient recruitment and engagement.

The value of CRO/Pharma strategic partnerships

  • 83%

    of respondents believe strategic partnerships with CROs will be important to the success of clinical trials over the next 5 years.
  • 21%

    say collaborative development with outsourced/virtual development partners will help improve clinical development efficiency.

In the ICON and Informa industry survey 'Improving Pharma R&D Efficiency', executives were asked 'How important will strategic partnerships with CROs be to the success of your clinical trials in the next 5 years?' With the growth in specialisation of clinical research, partnerships between sponsors and CROs are likely to grow in value.